Sanofi S.A. stock (FR0000120578): analyst consensus steady as ADRs trade in low-40s USD range

Sanofi shares remain anchored on Euronext Paris while the company’s Nasdaq ADRs change hands around the low-40s USD mark, broadly aligning with a hold consensus from Wall Street analysts as of late May 2026.

Sanofi shares stayed broadly aligned with analyst expectations heading into June, with the company’s American Depositary Receipts (ADRs) on Nasdaq closing at USD 43.67 on 05/29/2026, while the primary listing in France continues to trade on Euronext Paris under the ticker SAN, according to MarketBeat as of 05/29/2026.

As a leading healthcare group headquartered in France, Sanofi remains a major component of the domestic equity market via its Euronext Paris listing, while the Nasdaq ADR line under ticker SNY provides a key access point for U.S. investors who track the stock in U.S. dollars and compare its performance to other large-cap pharmaceutical names.

The stock traded at USD 43.67 on 05/29/2026 on Nasdaq, according to MarketBeat as of 05/29/2026.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Sanofi
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: Paris, France
• Core markets: Europe, United States, global emerging markets
• Key revenue drivers: Specialty care, vaccines, and general medicines portfolios
• Home exchange/listing venue: Euronext Paris (SAN)
• Trading currency: EUR

Sanofi S.A.: core business model

Sanofi focuses on researching, developing, and commercializing prescription medicines and vaccines, with sales concentrated in specialty care therapies, an expanded vaccines franchise, and established general medicines that together shape its revenue profile.

What banks and research houses say about Sanofi S.A.

MarketBeat’s compilation of broker views as of 05/29/2026 indicates that 15 Wall Street analysts covering Sanofi’s Nasdaq-listed ADRs currently assign the shares a consensus rating of "Hold", reflecting a neutral stance rather than a clear bias toward either positive or negative expectations, according to MarketBeat as of 05/29/2026.

The same MarketBeat survey reports an average 12-month price target of USD 51.00 for the ADR line, with individual targets ranging from USD 50.00 to USD 52.00, which implies potential upside of about 16.78% from the 05/29/2026 close of USD 43.67 if those projections materialize over the coming year, based on MarketBeat as of 05/29/2026.

Conclusion

Sanofi shares, reflected by the Nasdaq ADR close of USD 43.67 on 05/29/2026, continue to trade in a range that broadly matches the prevailing hold consensus from Wall Street analysts while the company remains firmly rooted in the French equity market via Euronext Paris.

The current analyst survey compiled by MarketBeat, with a USD 51.00 average 12-month price target and a neutral overall recommendation, provides investors with a reference framework as they monitor how Sanofi’s portfolio and strategic initiatives may influence the stock’s performance over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.